Neuropsychopharmacology, Journal Year: 2024, Volume and Issue: 50(1), P. 230 - 245
Published: July 1, 2024
Language: Английский
Neuropsychopharmacology, Journal Year: 2024, Volume and Issue: 50(1), P. 258 - 268
Published: Aug. 21, 2024
Abstract Neuroimaging, across positron emission tomography (PET), electroencephalography (EEG), and magnetic resonance imaging (MRI), has been a mainstay of clinical neuroscience research for decades, yet penetrated little into psychiatric drug development beyond often underpowered phase 1 studies, or care. Simultaneously, there is pressing need to improve the probability success in development, increase mechanistic diversity, enhance efficacy. These goals can be achieved by leveraging neuroimaging precision psychiatry framework, wherein effects drugs on brain are measured early understand dosing indication, then later-stage trials identify likely responders enrich trials, ultimately improving outcomes. Here we examine key variables important using from lens biotechnology pharmaceutical companies developing deploying new psychiatry. We argue that clear paths incorporating different modalities de-risk subsequent phases near intermediate term, culminating use select care prescription drugs. Better outcomes through biomarkers, however, require wholesale commitment approach will necessitate cultural shift align biopharma orientation already routine other areas medicine.
Language: Английский
Citations
5
Biological Psychiatry Cognitive Neuroscience and Neuroimaging, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 1, 2024
Intermittent theta burst stimulation (iTBS) of the dorsolateral prefrontal cortex (DLPFC) is widely applied as a therapeutic intervention in mental health; however, understanding its mechanisms still incomplete. Prior magnetic resonance imaging (MRI) studies have mainly used offline iTBS or short sequences concurrent transcranial (TMS)-functional MRI (fMRI). This study investigated full 600-stimuli protocol using interleaved TMS-fMRI comparison with 2 control conditions healthy subjects. In crossover design, 18 participants underwent 3 sessions iTBS-fMRI: 1) left DLPFC at 40% resting motor threshold (rMT) intensity, 2) 80% rMT and 3) primary (M1) intensity. We compared immediate blood oxygen level-dependent (BOLD) responses during iTBS-fMRI across these including correlations between individual fMRI BOLD activation iTBS-induced electric field strength target sites. Whole-brain analysis showed increased several regions following iTBS. Specifically, DLPFC, well bilateral M1, anterior cingulate cortex, insula, stimulation. Increased activity was observed neither nor M1 iTBS, whereas other found to overlap conditions. Of note, intensities were only correlated for not dosage- target-specific individuals. Future may use our approach investigating engagement clinical samples.
Language: Английский
Citations
5
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: April 9, 2024
Abstract Transcranial magnetic stimulation (TMS) and deep brain (DBS) can treat some neuropsychiatric disorders, but there is no consensus approach for identifying new targets. We localized causal circuit-based targets anxiety that converged across multiple natural experiments. Lesions (n=451) TMS sites (n=111) modify mapped to a common normative circuit (r=0.68, p=0.01). In an independent dataset (n=300), individualized site connectivity this predicted change (p=0.02). Subthalamic DBS overlapping the caused more (n=74, p=0.006), thus demonstrating network-level effect, as was derived without any subthalamic sites. The specific trait versus state in datasets measured both (p=0.003). Broadly, illustrates pathway discovering novel disorders.
Language: Английский
Citations
4
Nature Mental Health, Journal Year: 2024, Volume and Issue: 2(7), P. 809 - 817
Published: April 26, 2024
Language: Английский
Citations
4
Neuropsychopharmacology, Journal Year: 2024, Volume and Issue: 50(1), P. 230 - 245
Published: July 1, 2024
Language: Английский
Citations
4